인공 망막 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 질환별, 용도별, 지역별 및 부문별 예측(2027-2033년)

Artificial Retina Market Summary

The global artificial retina market size is valued at USD 3.3 million in 2026 and is projected to grow from USD 6.9 million in 2027 to USD 25.2 million by 2033, at a CAGR of 33.6% from 2027 to 2033. Europe dominated the market, accounting for the largest revenue share of 100.0% in 2026. Artificial retina systems, also known as retinal prostheses or retinal implants, are implantable electronic devices designed to stimulate surviving retinal neurons or downstream visual pathways when photoreceptor cells have been permanently damaged.

These systems typically comprise an implantable microelectronic chip, an external camera, an image processing unit, and wireless communication technology that together convert visual information into electrical signals interpretable by the visual system. The current commercial landscape for artificial retina systems remains highly nascent. As of 2026, PRIMA is the only artificial retina system that has entered commercialization, following the receipt of CE Mark approval in July 2026 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.

Commercial availability is currently limited to Europe, with initial rollout focused on selected specialized retinal centers while reimbursement processes and broader site activation continue across the region. Earlier-generation retinal prostheses, including the Argus II, Alpha IMS, Alpha AMS, and IRIS II systems, have been discontinued due to limited commercial adoption and strategic business decisions, resulting in a significant gap between historical and current commercialization. Consequently, the global artificial retina industry is presently driven primarily by the initial European commercialization of PRIMA, with future market expansion expected to depend on additional regulatory approvals, geographic expansion, reimbursement adoption, and the commercialization of next-generation retinal prosthesis technologies.

Artificial retina implant (ARI) technologies are primarily being developed for patients with retinitis pigmentosa (RP), advanced age-related macular degeneration (AMD), Stargardt disease, and other inherited retinal dystrophies, for whom conventional medical or surgical treatments offer limited or no restoration of vision. Growing investments in neurotechnology, bioelectronics, and vision restoration research are supporting the continued development of the artificial retina implant (ARI) market. One of the primary factors driving market growth is the increasing prevalence of retinal degenerative diseases globally. Inherited retinal degenerations affect more than 5.5 million people globally, while age-related macular degeneration remains one of the leading causes of irreversible blindness among older adults.

Population aging, greater awareness of inherited retinal disorders, improved genetic testing, and earlier diagnosis are expanding the pool of patients who may benefit from advanced vision restoration technologies. For instance, In January 2026, the New England Journal of Medicine (NEJM) published the PRIMA clinical trial and an accompanying editorial recognizing the PRIMA subretinal photovoltaic implant as the first treatment to restore vision in patients with advanced geographic atrophy due to age-related macular degeneration (AMD). The study demonstrated clinically meaningful improvements in visual acuity in the majority of implanted patients, marking a significant milestone in the advancement of artificial retina technology and vision restoration research.

Another major driver is the rapid advancement of retinal prosthesis technology and neuroengineering. Continuous innovations in microelectronics, photovoltaic implants, wireless power transfer, high-density electrode arrays, artificial intelligence-enabled image processing, and miniaturized implant designs are significantly improving the performance and safety of artificial retina systems. These technological developments are enabling higher visual resolution, improved implant stability, and enhanced patient outcomes compared with earlier generations of retinal prostheses.

Global Artificial Retina Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2027 to 2033. For this study, Grand View Research has segmented the global artificial retina market report based on product, disease indication, end-use, and region:

• Product Outlook (Revenue, USD Million, 2027 - 2033)
• Epiretinal Implants
• Subretinal Implants
• Suprachoroidal Implants
• Disease Indication Outlook (Revenue, USD Million, 2027 - 2033)
• Retinitis Pigmentosa
• Dry Age-Related Macular Degeneration (Geographic Atrophy)
• Stargardt disease
• Other Inherited Retinal Dystrophies (IRD)
• End Use Outlook (Revenue, USD Million, 2027 - 2033)
• Hospitals
• Specialty Eye Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2027 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
  • India
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease Indication
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Disease Indication outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Artificial Retina Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Artificial Retina Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Artificial Retina Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Artificial Retina Market: Product Movement Analysis
• 4.3. Artificial Retina Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
• 4.5. Epiretinal Implants
  • 4.5.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
• 4.6. Subretinal Implants
  • 4.6.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
• 4.7. Suprachoroidal Implants
  • 4.7.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 5. Artificial Retina MaDisease Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Artificial Retina Market: Disease Indication Movement Analysis
• 5.3. Artificial Retina Market by Disease Indication Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
• 5.5. Retinitis Pigmentosa
  • 5.5.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
• 5.6. Dry Age-Related Macular Degeneration (AMD) (Geographic Atrophy)
  • 5.6.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
• 5.7. Stargardt disease
  • 5.7.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
• 5.8. Other Inherited Retinal Dystrophies (IRD)
  • 5.8.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 6. Artificial Retina Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Artificial Retina Market: End Use Movement Analysis
• 6.3. Artificial Retina Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
• 6.5. Hospitals
  • 6.5.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
• 6.6. Specialty Eye Clinics
  • 6.6.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 7. Artificial Retina Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Artificial Retina Market Movement Analysis
• 7.3. Artificial Retina Market: Regional Estimates & Trend Analysis by Product & Disease Indication
• 7.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Science Corporation
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Cortigent (Subsidiary of Vivani Medical, Inc.)
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Nano Retina
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Bionic Vision Technologies
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. iBIONICS
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Optobionics Corporation
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Monash Vision Group
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. NIDEK CO., LTD.
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives